Cellectar Biosciences Reports Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel, Says CLR 1602 Tumor Selectivity ~30 Times Greater Than Paclitaxel Alone